In a 12‑year‑old patient with anxiety and depression, no documented episodes of mood instability, but currently experiencing mood swings with depressive symptoms, should treatment be started with monotherapy (e.g., an SSRI) or should a mood stabilizer be added now?

Start with SSRI Monotherapy

In a 12-year-old with anxiety and depression experiencing mood swings but no documented bipolar episodes, initiate treatment with SSRI monotherapy rather than adding a mood stabilizer now. The mood swings described are most likely manifestations of the underlying anxiety and depression, not bipolar disorder, and do not warrant preemptive mood stabilizer use 1, 2.

Rationale for SSRI Monotherapy

SSRIs represent the first-line pharmacological intervention for both anxiety and depressive disorders in children and adolescents 3. The evidence strongly supports starting with monotherapy:

• Fluoxetine has the strongest evidence base for adolescent depression, with response rates of 47-69% versus 33-57% for placebo 2
• The number needed to treat is 3 for achieving response, far outweighing the number needed to harm of 143 for suicidal ideation 1
• Combination therapy (SSRI + CBT) shows superior outcomes to either alone, but this refers to psychotherapy, not mood stabilizers 2, 4

Why Not Add a Mood Stabilizer Now

Mood stabilizers are indicated when there is documented bipolar disorder or clear manic/hypomanic episodes 5, 6. Your patient has:

• No documented episodes of mood instability (per your description)
• Mood swings with depressive symptoms, which are common in anxiety and depression themselves
• No mention of manic symptoms (decreased need for sleep, grandiosity, pressured speech, etc.)

Critical distinction: Behavioral activation from SSRIs (restlessness, impulsiveness, disinhibition) typically occurs early in treatment or with dose increases and resolves quickly with dose reduction. True mania/hypomania appears later and persists despite SSRI discontinuation, requiring active intervention 1. This distinction should guide your monitoring, not preemptive polypharmacy.

Implementation Strategy

Starting Treatment:

• Begin with fluoxetine or sertraline as first-line agents 2, 3
• Use slow up-titration to minimize behavioral activation risk, which is higher in younger children 1
• Expect clinically significant improvement by week 6, maximal improvement by week 12 or later 1

Monitoring Protocol:

• Close monitoring in the first month for behavioral activation (motor restlessness, insomnia, impulsiveness, aggression) 1
• Watch for suicidality, especially in first months and after dose adjustments 1
• If true mania/hypomania emerges (persistent elevated mood, decreased sleep need, grandiosity appearing later in treatment), then reassess for bipolar disorder and consider mood stabilizers 1

Common Pitfalls to Avoid

Do not confuse behavioral activation with bipolar disorder. Behavioral activation is:

• More common in younger children and anxiety disorders 1
• Occurs early (first month) or with dose increases
• Resolves quickly with dose reduction
• Does not require mood stabilizers

Do not preemptively add mood stabilizers based on "mood swings" alone. This approach:

• Lacks evidence in patients without documented bipolar episodes
• Exposes the patient to unnecessary medication side effects
• Complicates the clinical picture when trying to assess SSRI response

If SSRI Monotherapy Fails:

Only after an adequate trial (12 weeks at therapeutic dose) should you consider:

• Switching to another SSRI
• Adding CBT if not already implemented 2, 4
• Augmentation strategies (but mood stabilizers still require bipolar diagnosis) 5

The key is careful monitoring, not prophylactic polypharmacy. Start simple, titrate slowly, and watch closely for true bipolar features rather than assuming they exist based on mood variability alone.